Dr. Maher is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1300 E Marshall St
Richmond, VA 23298Phone+1 804-828-7999
Education & Training
- University of Arizona College of Medicine-TucsonFellowship, Hematology and Medical Oncology, 2014 - 2017
- University of Arizona College of Medicine-TucsonResidency, Internal Medicine, 2011 - 2014
- College of Osteopathic Medicine of the PacificClass of 2011
Certifications & Licensure
- VA State License 2020 - 2026
- AZ State License 2011 - 2021
- WA State License 2016 - 2017
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- A Study to Evaluate Safety and Efficacy of Selinexor Versus Treatment of Physician's Choice in Participants With Previously Treated Myelofibrosis Start of enrollment: 2021 Mar 17
Roles: Principal Investigator, Contact
- Study of Selinexor in Combination With Ruxolitinib in Myelofibrosis Start of enrollment: 2021 Mar 11
Roles: Principal Investigator, Contact
Publications & Presentations
PubMed
- 2 citationsPrevention and management of infections after exposure to ionizing radiation.Keri R. Maher, Ian M. Bouligny, Andrew M. Yeager
Journal of Radiological Protection. 2021-07-15 - 8 citationsVenetoclax with decitabine or azacitidine in the first-line treatment of acute myeloid leukemia.Ian M Bouligny, Graeme Murray, Michael Doyel, Tilak Patel, Josh Boron
Ejhaem. 2023-05-01 - 13 citationsMechanisms of myeloid leukemogenesis: Current perspectives and therapeutic objectives.Ian M Bouligny, Keri R Maher, Steven Grant
Blood Reviews. 2023-01-01
Press Mentions
- Venetoclax-Based Strategies in Patients with Secondary-Type Mutations, Acute Myeloid LeukemiaDecember 12th, 2023
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: